Agios to Present Clinical and Preclinical Data at the 20th Congress of the European Hematology Association
New Data from Three Lead Programs in IDH Mutant Positive Cancers and PK Deficiency
Company to Host Conference Call and Webcast on
“EHA is an important meeting for us this year as we share new and
encouraging data for each of our three lead clinical programs,” said
Highlights of selected data presentations include:
AG-221: a first-in-class, oral, selective, potent inhibitor of the mutated IDH2 protein
-
A poster presentation will provide new safety and efficacy data from
the ongoing Phase 1 study of AG-221 in advanced IDH2-mutant
hematologic malignancies, including longer follow-up data, additional
patients and early molecular data from the Phase 1 dose escalation
study, in addition to initial data from the expansion cohorts
initiated in
October 2014 .
AG-120: a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein
-
A poster presentation will provide new safety and efficacy data from
the ongoing Phase 1 study of AG-120 in advanced IDH1-mutant
hematologic malignancies, including longer follow-up data and
additional patients since the initial data presentation in
November 2014 at the 26th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
AG-348: a novel, first-in-class, oral activator of pyruvate kinase-R (PKR) for the treatment of pyruvate kinase (PK) deficiency
- An oral presentation for AG-348 will include the final data showing safety, tolerability, pharmacokinetic data and effects on pharmacodynamics markers from the multiple ascending dose escalation (MAD) study in healthy volunteers.
- A poster presentation and an e-poster from Boston Children’s Hospital will show the first data from a natural history study of PK deficiency.
The accepted abstracts are listed below and are now available online on the EHA conference website: http://www.ehaweb.org/congress-and-events/annual-congress-2/20th-congress/.
The schedule for the oral presentation by Agios is as follows:
Date & Time:
Title:
Phase 1 Multiple Ascending Dose Study of the Safety, Tolerability,
and Pharmacokinetics/Pharmacodynamics of AG-348, a First-in-class
Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects
Session:
Red Cells: Novel Clinical Aspects
Abstract: S138
Location:
Room Strauss 1
Presenter: Sam Agresta, M.D., M.P.H., T.M.,
The details for poster presentations and e-posters by Agios and/or its collaborators are as follows:
Date & Time:
Title:
Categorization of Clinical Severity in Pyruvate Kinase Deficiency (PKD)
in an International, Observational Cohort
Session:
Abstract: P375
Location:
Poster area (Hall C)
Presenter: Rachael Grace, M.D.,
Dana-Farber Boston Children's Cancer and Blood Disorder Center
Date & Time:
Title:
AG-221, An Oral, Selective, First-in-class, Potent Inhibitor of the IDH2
Mutant Enzyme, Induced Durable Responses in a Phase 1 Study of IDH2
Mutation-Positive Advanced Hematologic Malignancies
Session:
Acute Myeloid Leukemia – Clinical 3
Abstract: P569
Location:
Poster area (Hall C)
Date & Time:
Title:
Clinical Safety and Activity of AG-120, a First-in-class, Potent
Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of Patients
with Advanced IDH1-Mutant Hematologic Malignancies
Session:
Acute Myeloid Leukemia – Clinical 3
Abstract: P563
Location:
Poster area (Hall C)
Date & Time:
Title:
Pharmacokinetic/Pharmacodynamic Evaluation of AG-120, a Potent Inhibitor
of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced
Hematologic Malignancies
Session: Acute Myeloid Leukemia -
Clinical
Abstract: P572
Location: Poster area
(Hall C)
Date & Time:
Title:
Preclinical Pharmacokinetic/Pharmacodynamic Relationships for AG-348, an
Investigational Small-Molecule Activator of Pyruvate Kinase
Session:
Non-malignant Hematopoietic Disorders
Abstract: P751
Location:
Poster area (Hall C)
E-Poster Title: Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of AG-221, a Potent Mutant IDH2 Inhibitor, from a Phase 1 Trial of Patients with IDH2-Mutation Positive Hematologic Malignancies
E-Poster Title: The Clinical Features and Treatment of Iron Overload in Pyruvate Kinase Deficiency (PKD): Data from the PKD Natural History Study (NHS)
Conference Call Information
Agios will host a conference call and webcast from the congress to
review the data on
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding the potential
benefits of Agios' product candidates targeting IDH1/IDH2 or pyruvate
kinase-R mutations, including
View source version on businesswire.com: http://www.businesswire.com/news/home/20150521005650/en/
Source:
Agios Pharmaceuticals, Inc.
Renee Leck, 617-649-8299
Senior
Manager, Investor Relations and Public Relations
Renee.Leck@agios.com